AI Guidance for Biopsy in Suspected Cholangiocarcinoma
Neoplasms, Non-Neoplastic, Bile Duct Neoplasms
About this trial
This is an interventional diagnostic trial for Neoplasms focused on measuring Artificial Intelligence, Cholangioscopy, cholangiocarcinoma, biopsy
Eligibility Criteria
Inclusion Criteria:
- Patients referred to our center with an indication of DSOC due to suspicion of CBD tumor or indeterminate CBD stenosis.
- Patients who authorized for DSOC-guided biopsy.
Exclusion Criteria:
- Any clinical condition which makes DSOC inviable.
- Patients with more than one DSOC.
- Lost on a six-month follow-up after DSOC.
Sites / Locations
- Carlos Robles-Medranda
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
DSOC + AI-biopsy guidance
DSOC biopsy without AI guidance
This group is comprised by patients with suggestive malignant biliary lesions assessed by DSOC for biopsy. In this group, the investigators aim to use as a complement tool an AI model for the detection of features suggestive of malignancy to perform the biopsy on the detecting bounding box signal. A further follow-up of 6 months is necessary for a confirming diagnosis of neoplastic lesions.
This group is comprised by patients with suggestive malignant biliary lesions assessed by DSOC for biopsy without AI guidance. A further follow-up of 6 months is necessary for a confirming diagnosis of neoplastic lesions.